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Abstract Background: To determine if global brain hypoperfusion and oxygen hypometabolism occur in pa-
tients with amnestic mild cognitive impairment (aMCI).
Methods: Thirty-two aMCI and 21 normal subjects participated. Total cerebral blood flow (TCBF),
cerebral metabolic rate of oxygen (CMRO2), and brain tissue volume were measured using color-
coded duplex ultrasonography (CDUS), near-infrared spectroscopy (NIRS), and MRI. TCBF was
normalized by total brain tissue volume (TBV) for group comparisons (nTCBF). Cerebrovascular re-
sistance (CVR) was calculated as mean arterial pressure divided by TCBF.
Results: Reductions in nTCBF by 9%, CMRO2 by 11%, and an increase in CVR by 13% were ob-
served in aMCI relative to normal subjects. No group differences in TBV were observed. nTCBF was
correlated with CMRO2 in normal controls, but not in aMCI.
Conclusions: Global brain hypoperfusion, oxygen hypometabolism, and neurovascular decoupling
observed in aMCI suggest that changes in cerebral hemodynamics occur early at a prodromal stage of
Alzheimer’s disease, which can be assessed using low-cost and bedside-available CDUS and NIRS
technology.
 2014 The Alzheimer’s Association. All rights reserved.
Keywords: Mild cognitive impairment; Cerebral blood flow; Cerebral metabolic rate of oxygen; Ultrasonography; Near-in-
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1. Introduction
Alzheimer’s disease (AD) may begin years and even de-
cades before its clinical appearance [1]. For early detection
or treatment of AD, the term mild cognitive impairment
(MCI), or the amnestic type of MCI (aMCI) in particular,
has been coined to describe a prodromal stage of AD
[2]. The etiology of sporadic AD is not clear and is likely
to be multifactorial involving genetic and environmental
factors [3].
Brain perfusion is fundamentally important for normal
neuronal function. Brain hypoperfusion, even insufficient
to produce ischemic cell death, can affect brain protein syn-
thesis and lead to neuronal dysfunction [4]. Accumulating
evidence suggests brain hypoperfusion/cerebrovascular dys-
function may play an important role in AD onset and pro-
gression [4]. In this regard, regional brain hypoperfusion
and hypometabolism have been observed in aMCI patients
mainly in the temporal-parietal lobe and posterior cingulate
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cortex [5]. However, an increase rather than a decrease in re-
gional brain perfusion also has been observed in aMCI and
has been interpreted to reflect a compensatory effect [6].
These observations reflect the complexity of changes in re-
gional brain perfusion and metabolism at a prodromal stage
of AD.
So far, few studies havemeasured global brain perfusion in
patients with aMCI and AD [7–9]. To our knowledge, only
one study reported that a reduction in global brain perfusion
in aMCI patients was related to the risk of AD conversion
[9]. Large population-based studies have demonstrated that
global brain hypoperfusion as indicated by a low cerebral
blood flow (CBF) velocity in the middle cerebral
artery (MCA) was related to the high risks for developing
AD in older adults [10]. The color-coded duplex ultrasonog-
raphy (CDUS) and spatially resolved near-infrared spectros-
copy (NIRS) are well established methods for measurement
of CBF and brain tissue oxygenation in human subjects
[11,12]. These methods are noninvasive, inexpensive,
and available at bedside; therefore, they have a great
potential to be used in large population studies. Using
these methods, this study tested the hypothesis that
reductions in global brain perfusion and cerebral metabolic
rate for oxygen utilization (CMRO2) occur in aMCI
patients relative to normal control subjects. Obtaining this
information may help us to better understand the role of
cerebrovascular dysfunction inAD onset and progression [4].
2. Methods
2.1. Participants
Thirty-two aMCI subjects and 21 normal cognitive con-
trols were recruited from local newspaper advertisements,
senior centers, and the University of Texas Southwestern
Medical Center Alzheimer’s Disease Center. The diagnosis
of aMCI was based on Petersen criteria [1] as modified by
the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
project (http://adni-info.org). Further clinical evaluation
was performed according to the Alzheimer’s Disease Coop-
erative Study (ADCS) recommendations (http://www.adcs.
org) using standard diagnostic criteria. The results of cogni-
tive assessment using the Mini-Mental State Examination
(MMSE) [13], Clinical Dementia Rating (CDR) scale [14],
and Wechsler Memory Scale Logical Memory (LM) for
immediate and delayed recalls are shown in Table 1. Inclu-
sion criteria for normal subjects and patients with aMCI
were both sexes and age 55w80 years. Exclusion criteria
were major psychiatric disorders, major or unstable medical
conditions, uncontrolled hypertension, diabetes mellitus, or
chronic inflammatory diseases. Subjects with a heart pace-
maker or anymetal plates or pins in their body that prevented
them from MRI were also excluded. Group demographics
and clinical features are presented in Table 1. All subjects
and/or their study partners signed the informed consent ap-
proved by the institutional review boards of the University
of Texas Southwestern Medical Center and Texas Health
Presbyterian Hospital of Dallas.
2.2. MRI measurement of brain tissue volume
Magnetization-prepared rapid acquisition gradient echo
(MPRAGE) images were acquired on a 3T system (Philips
Achieva MR system) to measure cortical and subcortical
brain tissue volumes. Sagittal images were obtained with
a field of view (FOV) of 256 ! 256 mm, a matrix size of
256! 256, and a slice thickness of 1mmwithout gap. Image
sequence parameters were repetition time (TR) 5 8.1 ms,
echo time (TE) 5 3.7 ms, inversion time (TI) 5 1100 ms,
shot interval 2100 ms, and flip angle (FA)5 12 with a sen-
sitivity encoding (SENSE) factor of 2. A total of 140 images
were collected to cover the whole brain. MPRAGE images
were processed using FreeSurfer software (http://nmr.mgh.
Table 1
Demographics and clinical characteristics of study participants
Variables NC (n 5 21) aMCI (n 5 32) P
Age, years 67 (7) 67 (7) .802
Education, years 16 (3) 16 (3) .874
Female sex, n (%) 13 (62%) 19 (59%) ..999
Race, n (%)
Caucasian 19 (90%) 29 (91%) ..999
African American 2 (10%) 3 (9%) ..999
Height, cm 169 (7) 167 (10) .432
Weight, kg 75 (16) 79 (17) .461
Body mass index, kg/m2 26.1 (4.2) 28.0 (4.3) .122
Hematocrit, % 41.7 (3.8) 41.4 (3.3) .767
ETCO2, mmHg 40.1 (2.9) 40.0 (3.9) .953
Blood pressure, mmHg
Systolic blood pressure 120 (12) 123 (11) .220
Diastolic blood pressure 72 (9) 74 (7) .250
MAP 88 (9) 91 (8) .194
Pulse pressure 48 (7) 49 (10) .591
HR, bpm 64 (8) 61 (9) .192
Cardiac output (echo), L/min 3.62 (0.88) 3.39 (1.00) .388
Medical history
Treated hypertension 9 (43%) 14 (44%) ..999
Hypercholesterolemia 7 (33%) 11 (34%) ..999
Hypothyroidism 3 (14%) 4 (13%) ..999
Medication use
Calcium-channel blocker 3 (14%) 5 (16%) ..999
b-blocker 3 (14%) 4 (13%) ..999
ARBs 2 (10%) 3 (9%) ..999
ACE inhibitors 4 (19%) 6 (19%) ..999
Diuretics 3 (14%) 4 (13%) ..999
Statin 4 (19%) 6 (19%) ..999
Psychometric test scores
MMSE 29.1 (0.8) 28.9 (1.4) .669
CDR 0 0.5 –
LM immediate recall 14.9 (1.8) 10.8 (2.3) ,.001
LM delayed recall 14.5 (2.6) 8.2 (2.2) ,.001
Abbreviations: NC, cognitively normal controls; aMCI, amnestic mild
cognitive impairment; ETCO2, end-tidal CO2; MAP, mean arterial pressure;
HR, heart rate; bpm, beats per minute; ARBs, angiotensin receptor blockers;
ACE, angiotensin converting enzyme;MMSE,Mini-Mental State Examina-
tion score; CDR, clinical dementia rating; LM, Wechsler Memory Scale
Logical Memory subtest.
NOTE. Values are the mean (standard deviation) or number (percentage).
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harvard.edu/martinos). Details of the procedures for measur-
ing brain tissue volume were published previously [15]. To-
tal brain tissue volume (TBV) was obtained as a sum of
measured cortical and subcortical gray matter (GM) and
white matter (WM) volumes, including the brainstem and
cerebellum. Intracranial volume (ICV) was measured using
the atlas-based spatial normalization procedures to delineate
cerebral spinal fluid (CSF)/skull borders [15]. Individual
TBV, GM, and WM volumes were divided by ICV to obtain
the normalized values (nTBV, nGM, and nWM).
2.3. Measurement of brain perfusion, tissue oxygenation,
and systemic hemodynamics
A 3- to 12-MHz linear array transducer on the CDUS sys-
tem (CX-50, Phillips Healthcare) was used for CBF mea-
surements. The CBF measurements for the internal carotid
artery (ICA) were performed at least 1 cm above the carotid
bulb (Fig. 1A), and for the vertebral artery (VA) they were
performed between the C4 and C6 intertransverse segments
(Fig. 1B). A straight vessel segment with a parallel wall
view was identified where the luminal diameter (D) re-
mained the same for a length of at least 0.5 cm to enhance
the uniformity of Doppler sample volume. The sample vol-
ume was positioned at this site to cover the entire vessel
lumen (Fig. 1, C and D) to measure the angle-corrected
mean velocity (i.e., spatially averaged blood flow velocity
across the whole vessel lumen assuming a laminar flow)
[16]. For calculation of volumetric blood flow, at least five
complete cardiac cycles of consecutive blood flow velocity
waveforms were recorded to obtain the time-averaged
mean velocity (TAMV) (Fig. 1, C and D). For vessel diam-
eter measurement, the distance between the parallel internal
layers at the sample volume site was measured (Fig. 1, A and
B). Specifically, pulsatile changes of the vessel diameter
were recorded continuously for approximately 5 seconds
on high-resolution B-mode video with a 21-Hz frame rate
in a longitudinal view for ICA and VA. Changes of vessel di-
ameter at the sampling segment (with a length ofw0.5 cm)
were measured using an edge-detection and wall-tracking
technology to obtain the time-averaged vessel diameter
from three consecutive cardiac cycles (Brachial and Carotid
Analyzer, Medical Imaging Applications). The velocity and
diameter measurements were repeated 3 times for each
vessel with their mean values used for CBF calculation.
This procedure was taken to reduce the intrinsic CBF vari-
ability associated with respiratory and other low-frequency
oscillations [17]. Blood flow of each vessel was calculated
as the product of the TAMV and the cross-sectional area
(A) of the vessels as CBF 5 TAMV ! A ! 60 5 TAMV
! [(D/2)2 ! P] ! 60. Total CBF (TCBF) was obtained
as a sum of CBFs of bilateral ICAs and VAs and was normal-
ized by TBV (nTCBF) for group comparisons.
Spatially resolved NIRS (NIRO-200NX, Hamamatsu
Photonics) was used to measure brain tissue oxygenation
(i.e., the ratio of intravascular oxygenated to total hemoglobin
concentration) expressed as a tissue oxygenation index (TOI)
[12]. This technology is based on the photon diffusion theory
to assess the slope of light attenuation versus the distances
traveled by the light to calculate absolute brain tissue oxygen
saturation and has been validated and used extensively to as-
sess brain tissue oxygenation under various clinical condi-
tions [18]. It has been shown that TOI can provide
a quantitative estimation of cerebral venous oxygenation un-
der certain model assumptions [19]. Thus, cerebral oxygen
extraction fraction (OEF) can be estimated as OEF 5
(SaO2 – TOI)/SaO2, in which SaO2 is the arterial blood oxy-
gen saturation; and CMRO2 can be calculated as CMRO2 5
nTCBF ! (SaO2 – TOI) ! (Ca/r) on the basis of Fick’s
law [20], in which Ca is the maximal amount of oxygen
that a unit volume of blood can carry (8.337 mmol/mL) [21]
and r is a constant of brain tissue density 1.06 g/mL [22].
Six aMCI subjects (three females) and three controls (two fe-
males) had no TOI measurements for technical problems.
Brachial arterial pressure was measured using a sphygmo-
manometer (Tango1, Suntech), and SaO2 was measured at
finger using a pulse oximeter (Biox 3700, Ohmeda). Cerebro-
vascular resistance (CVR) was calculated as mean arterial
pressure (MAP) divided by TCBF (CVR 5 MAP/TCBF).
Electrocardiograph (Hewlett-Packard) wasmeasured to deter-
mine heart rate (HR). End-tidal CO2 (ETCO2) was monitored
with a capnograph (Capnogard, Novamatrix). Cardiac output
was measured with echocardiography from the apical four-
chamber view using a modified Simpson’s rule method [23].
All data collections were performed in the supine position
after at least 20 minutes of rest in an environmentally con-
trolled laboratory with an ambient temperature of 23C to al-
low stabilization of systemic and cerebral hemodynamics.
Subjects were asked to refrain from high-intensity exercise,
alcohol, or caffeinated beverage at least 24 hours before the
test. The time used for vascular imaging and blood flowmea-
surement using CDUS was approximately 20 minutes for
each individual subject. HR, TOI, and ETCO2 were recorded
continuously using data acquisition software (Acknowledge,
BIOPAC Systems) and averaged for data analysis. Thus, the
total time used for the test including supine rest was approx-
imately 40minutes. During data collection, subjects were in-
structed not to speak and were not cognitively engaged (e.g.,
reading, watching TV etc.). The experimental protocol was
the same for aMCI and normal subjects to minimize poten-
tial influences of differences in cognitive activity on the CBF
and TOI measurements [24].
Clinical cognitive assessments, measurements of cerebral
hemodynamics, and MRI were performed during three
visits. The time intervals among these visits were more
than 1 week but less than 3 months.
2.4. Measurement reproducibility
Fifteen individuals were randomly selected from the 21
normal subjects to assess the CBF and TOI measurement
reproducibility. Two measurements were obtained within
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a time period of 3 months. The coefficients of variation
between the measurements for TCBF and TOI were 4.7%
and 5.5%, respectively. Bland-Altman plots confirmed that
test-retest differences were distributed within a mean differ-
ence6 2 standard deviations (SD) without systemic bias for
TCBF (–3 6 48 mL/min) and TOI (0.2 6 7.2%).
2.5. Statistical analysis
Data were presented as mean 6 SD. Group comparisons
were performed using independent sample t tests for contin-
uous variables or c2 tests for categorical variables. The rela-
tionship between brain perfusion and CMRO2 was examined
using Pearson product-moment correlation analysis to assess
neurovascular coupling. P, .05 was considered statistically
significant.
3. Results
The aMCI and normal subjects were similar with respect
to age, sex, education, body size, hematocrit, ETCO2, blood
pressure, and cardiac output (Table 1). No differences in ei-
ther absolute (TBV, GM, and WM) or normalized brain vol-
umes (nTBV, nGM, and nWM) were observed between the
two groups (Table 2).
No group difference in diameter, blood flow velocity, or
CBF was found in bilateral ICAs and VAs, although a trend
of lower TCBF (w7%) was observed in aMCI subjects rel-
ative to normal controls (547 6 97 vs. 588 6 101 mL/min,
P 5 .142) (Table 2). Notably, nTCBF was reduced signifi-
cantly by 9% (48.1 6 8.3 vs. 53.1 6 8.7 mL/min/100 mL,
P , .05, Fig. 2A) in aMCI relative to the normal controls
associated with an significant increase in CVR by 13%
(0.171 6 0.033 vs. 0.152 6 0.025 mmHg$min/mL,
P , .05, Fig. 2B).
TOI and OEF also showed no group differences. How-
ever, CMRO2 was reduced significantly by 11% in aMCI rel-
ative to normal controls (113.6 6 15.7 vs. 127.1 6 17.1
mmol/100 g/min, P , .05, Fig. 2C).
Finally, a significant correlation between nTCBF and
CMRO2 (r 5 0.556, P , .05, Fig. 3A) was observed in nor-
mal controls but not in aMCI (Fig. 3B).
4. Discussion
In this study, we found that global brain perfusion and
CMRO2 were reduced and CVR was increased significantly
in aMCI patients as compared with normal controls. Further-
more, a linear correlation between nTCBF and CMRO2 was
found in normal subjects but not in aMCI, suggesting the
presence of neurovascular decoupling in these patients.
Taken together, these findings suggest that cerebral hemody-
namics or CBF regulation is compromised at a prodromal
stage of AD, which can be assessed using low-cost and
bedside-available CDUS and NIRS technology.
4.1. Methodological considerations
Numerous imaging modalities have been used to mea-
sure brain perfusion and the metabolic rate of oxygen or
Fig. 1. Measurements of cerebral blood flow in internal carotid artery (ICA) and vertebral artery (VA). (A) Diameter of ICA on high-resolution B-mode video
was measured using an automated wall-tacking and edge-detection software (see text). (B) Diameter of VAwas measured in the same way. (C) Measurement of
time-averaged mean velocity (TAMV) at ICA. (D) Measurement of TAMVat VA.
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glucose, including positron emission tomography (PET),
single-photon emission computed tomography (SPECT),
and perfusion MRI [25]. These methods in general are
expensive, are not available at the bedside, and are
used mainly at academic research centers. In addition,
these modalities either require injection of radioactive
tracers (PET and SPECT) or are not feasible in patients
who may have claustrophobia or metal implants in their
body (MRI). This study demonstrated the feasibility of
using noninvasive, low-cost, bedside-available CDUS
and NIRS methods to measure brain perfusion and
CMRO2 in aMCI patients. Further studies using these
technologies to assess changes in cerebral hemodynam-
ics in aMCI or AD in longitudinal or interventional stud-
ies are likely to establish its value in the clinical study
of AD.
Two technical issues related to the use of CDUS for mea-
suring CBF deserve attention. First, in this study, blood ve-
locity in a given vessel was measured using the TAMV
across thewhole vessel lumen over at least five complete car-
diac cycles. Thus, the obtained TAMV represents the spatial
(across the whole vessel lumen) and temporal (five or more
cardiac cycles) averaged blood velocity [16]. Under steady-
state conditions, TAMV is the most accurate index used for
CBF calculation when compared with other methods [26].
Second, for CBF calculation that is based on the product
of TAMVand the vessel luminal area, the importance of ves-
sel diameter measurement cannot be overemphasized. In the
study presented here, high-resolution (z0.01 mm) longitu-
dinal views of the ICA and VAwere acquired and the vessel
diameter was measured using an automated edge-detection
and wall-tracking software (Fig. 1, A and B) [27]. These pro-
cedures enhanced the accuracy and reliability of vessel di-
ameter measurements by avoiding the potential manual
measurement errors and/or the rater’s subjective bias. Fur-
thermore, the vessel diameter waveforms over the consecu-
tive cardiac cycles were averaged to minimize the influences
of diameter pulsatility on the blood flow calculation. With
these improvements in the methodology, TCBF measured
using CDUS was remarkably consistent with the reported
values using the standard Kety-Schmidt method [28].
Spatially resolved NIRS was used to measure brain tissue
oxygenation expressed as TOI [12]. It should be realized that
TOI reflects a mixture of intravascular oxygenation status
from the veins, arteries, and capillaries with a proportion
of approximately 75:20:5 in adults [29]. Under steady-
state conditions, changes in TOI reflect primarily changes
in cerebral venous oxygen saturation [30,31]. In the study
presented here, no group differences in arterial oxygen
saturation were observed. Thus, CMRO2 can be estimated
based on Fick’s law [20] by using TOI as a surrogate for ce-
rebral venous oxygen saturation.
It is likely that CMRO2 assessed in this study reflects pri-
marily cortex oxygen utilization because TOI measured from
the forehead is likely to be lower than the internal jugular vein
oxygen saturation, which also incorporates blood from the
deep brain structures that generally extract less oxygen
[32]. In addition, assessment ofCMRO2 assumed that the pro-
portional contributions of blood oxygenation from the veins,
arteries, and capillaries to the TOI did not differ between pa-
tients with aMCI and the normal controls. Verification of this
assumption needs to be determined in future studies.
4.2. Brain hypoperfusion, increases in CVR, and reduction
of CMRO2 in aMCI
Regional brain hypoperfusion and a reduction in the met-
abolic rate of glucose have been observed in aMCI patients in
the temporal-parietal lobe and posterior cingulate cortex sim-
ilar to that observed in patients with AD [33,34]. These
Table 2
Measurements of brain volume, perfusion, and tissue oxygenation
Variables NC (n 5 21) aMCI (n 5 32) P
Brain volume
ICV, mL 1516 (212) 1550 (212) .561
TBV, mL 1110 (98) 1140(107) .299
GM, mL 608 (47) 611 (56) .852
WM, mL 502 (56) 529 (57) .088
nTBV, %ICV 73.9 (6.9) 74.1 (5.3) .938
nGM, %ICV 40.6 (4.6) 39.7 (3.1) .393
nWM, %ICV 33.3 (2.7) 34.3 (2.7) .177
Regional brain perfusion
Diameter, mm
RICA 4.55 (0.74) 4.35 (0.61) .290
LICA 4.49 (0.52) 4.48 (0.66) .950
RVA 3.12 (0.62) 3.04 (0.45) .581
LVA 3.21 (0.47) 3.20 (0.48) .925
TAMV, cm/s
RICA 24.3 (7.7) 24.4 (6.8) .938
LICA 22.5 (7.5) 21.6 (6.6) .663
RVA 15.0 (4.7) 14.6 (5.8) .773
LVA 15.0 (3.0) 14.5 (3.9) .600
CBF, mL/min
RICA 233 (80) 211 (46) .211
LICA 207 (58) 201 (64) .756
RVA 73 (36) 64 (30) .349
LVA 76 (31) 70 (27) .492
Global brain perfusion
TCBF, mL/min 588 (101) 547 (97) .142
nTCBF, mL/min/100 mL 53.1 (8.7) 48.1 (8.3) .038
CVR, mmHg$min/mL 0.152 (0.025) 0.171 (0.033) .029
Brain tissue oxygenation indices
SaO2, % 97.0 (1.6) 97.2 (1.3) .570
TOI, % 66.4 (4.1) 65.5 (5.6) .562
OEF, % 31.4 (4.3) 32.5 (5.9) .524
CMRO2, mmol/100 g/min 127.1 (17.1) 113.6 (15.7) .010
Abbreviations: NC, cognitively normal controls; aMCI, amnestic mild
cognitive impairment; ICV, intracranial volume; TBV, total brain-tissue vol-
ume; WM, white matter; GM, gray matter; nTBV, normalized TBV; nWM,
normalizedWM; nGM, normalized GM; RICA, right internal carotid artery;
LICA, left internal carotid artery; RVA, right vertebral artery; LVA, left ver-
tebral artery; TAMV, time-averaged mean velocity; CBF, cerebral blood
flow; TCBF, total CBF; nTCBF, normalized TCBF; CVR, cerebrovascular
resistance; SaO2, arterial blood oxygen saturation; TOI, tissue oxygenation
index; OEF, oxygen extraction fraction5 (SaO2 – TOI)/SaO2; CMRO2, ce-
rebral metabolic rate of oxygen5 nTCBF! (SaO2 – TOI)! (8.337/1.06).
NOTE. Values are the mean (standard deviation).
J. Liu et al. / Alzheimer’s & Dementia 10 (2014) 162–170166
observations have been interpreted to reflect a reduced
neuronal activity in these regions at a prodromal stage of
AD [35].However, changes in regional brain perfusion orme-
tabolism in aMCI patients are inconsistent and likely to be
a dynamic process associated with AD progression [6]. In ad-
dition, changes in brain perfusion or metabolism could be
complicated by the presence of heterogeneous regional neural
and/or vascular compensatory mechanisms [36]. For exam-
ple, increases rather than decreases in brain perfusion [37]
or neuronal activity [38] have been observed in the prefrontal
lobe or hippocampus in aMCI patients despite the presence of
regional brain atrophy [39]. Thus, spatially heterogeneous
changes in regional brain perfusion or metabolism in aMCI
may lead to non-net changes in total brain perfusion.
Using the CDUS method, a few studies have documented
global brain hypoperfusion in AD patients [7,8]; and only
one study of aMCI has reported a reduced TCBF in those
patients who converted to AD after 2 years of follow-up
when compared with nonconverters [9]. These findings are
consistent with the large population-based studies that
showed that low CBF velocity measured using transcranial
Doppler (TCD) was related to a high risk of developing
AD in older adults [10]. The study presented here demon-
strated for the first time that global volumetric CBF mea-
sured using CDUS was reduced in aMCI patients when
compared with normal controls with similar demographic
characteristics and cardiovascular risk factors and that re-
duction in CBF in aMCI was associated with a significant in-
crease in CVR.
It is interesting to note that increases in CVR also have
been observed in aMCI patients in a recent study based on
TCDmeasurement of CBF velocity in the MCA. In addition,
the obtained CVR index for aMCI was between those of the
normal controls and patients with AD [40]. The study pre-
sented here extends these findings by having a larger sample
size and used global measurement of volumetric CBF. Of
note, because blood pressure was similar between the
groups, increases in CVR suggest the presence of cerebral
vasoconstriction in aMCI. It is possible that impairment of
cerebral endothelial function and/or brain amyloid-b deposi-
tion on the vessel wall may lead to cerebral vasoconstriction
in aMCI [41–43].
Furthermore, associated with changes in cerebral hemo-
dynamics, a recent study found that cardiac baroreflex gain
Fig. 2. Box plots of (A) normalized total cerebral blood flow (nTCBF), (B) cerebrovascular resistance (CVR), and (C) cerebral metabolic rate of oxygen
(CMRO2) in cognitively normal controls (NC) and amnestic mild cognitive impairment (aMCI) group. The horizontal dotted and solid lines within the box
represent the mean and median, respectively. *P , .05.
Fig. 3. Linear correlation analyses between cerebral metabolic rate of oxygen (CMRO2) and normalized TCBF (nTCBF) in cognitively normal controls (NC)
(A, solid dots) and amnestic mild cognitive impairment (aMCI) group (B, open circles). CMRO2 showed a significant correlation to TCBF in NC but not the
aMCI group. r 5 Pearson’s correlation coefficient.
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was also reduced in aMCI patients who had values between
those of the normal controls and AD patients [44]. The un-
derlying mechanism(s) between changes in cerebral hemo-
dynamics and baroreflex function in aMCI are not clear.
However, these findings do suggest that progressive changes
in peripheral and central hemodynamics are associated with
AD progression [44].
Finally, in this study, we found that CMRO2 was reduced
in aMCI patients. Because SaO2 and TOI did not differ be-
tween the groups, reduction in CMRO2 in aMCI could be
simply due to a reduction in CBF, reflecting decreases in
brain neuronal activity. On the other hand, a primary reduc-
tion in CBF due to vascular dysfunction can lead to a reduc-
tion in CMRO2 [4]. The cause-effect relationship cannot be
determined in this study.
4.3. Neurovascular decoupling in aMCI
Neurovascular coupling generally refers to increases in
regional brain blood flow in response to brain activation
[4]. Under resting conditions, global brain perfusion is also
related to the brain volume and/or brain oxidative metabolic
rate [45]. This view of neurovascular coupling is consistent
with the findings that in the normal subjects, brain perfusion
(nTCBF) was correlated with CMRO2 (Fig. 3A). The new
findings of the study presented here are that the neurovascu-
lar coupling relationship observed in normal subjects ap-
pears to be diminished in patients with aMCI (Fig. 3B).
The underlying mechanisms for these observations cannot
be determined in this study. It is possible that the presence
of compensatory mechanisms or dysregulation of brain per-
fusion or metabolism may have led to the observed neuro-
vascular decoupling in aMCI.
4.4. Strengths and limitations
Strengths of this study include that all normal subjects
were strictly screened and matched to aMCI patients, which
allowed us to study the main influence of aMCI by balancing
other confounding factors thatmay affect brain perfusion and
metabolism (Table 1). Another strength of this study is the
use of low-cost and bedside-available CDUS and NIRS
methods to measure brain perfusion and CMRO2. Both of
these methods are readily available in clinical settings and
can be applied in large population studies. In addition, the au-
tomated method used for vessel diameter measurement is
likely to enhance the accuracy and reliability of CBF mea-
surements. However, it should be noted that brain perfusion
and CMRO2 values overlapped considerably among individ-
uals with andwithout aMCI, although statistically significant
differences between group-averaged mean values were ob-
served (Figs. 2 and 3). Thus, further studies are needed to es-
tablish the sensitivity and specificity of using these
measurements for the clinical screening of individuals with
aMCI or early AD. In addition, a major limitation of these
methods is their low spatial resolution for CBF and brain
tissue oxygenation measurement. Using these methods, this
study was only able to differentiate CBF between the ICAs
and VAs (Table 2). Potential changes in more specific re-
gional brain perfusion andmetabolismmay not be detectable
either because of the presence of collateral blood flow and/or
neuronal/vascular compensatory mechanisms [5,6]. Another
limitation is the use of TOI as a surrogate of cerebral venous
oxygenation for CMRO2 calculation, which may lead to
an underestimated or overestimated absolute CMRO2.
However, measurement of TOI was performed in the same
way in aMCI patients as in the normal controls. Thus,
a systematic bias, if it indeed existed, should have had less
influence on the group differences observed in the study
presented here. Of note, we also did not find any
correlations between the measured LM scores (immediate
and delayed recalls) and cerebral hemodynamics in this
study (data not shown). Whether changes in cerebral
hemodynamics in aMCI indeed are correlated with changes
in cognitive function needs to be determined in
longitudinal studies. In this regard, the cross-sectional nature
of this study also limits its ability to draw conclusions regard-
ing the cause-effect relationship between changes in cerebral
hemodynamics and aMCI.
4.5. Summary of main findings
This study demonstrated for the first time that global
brain perfusion and CMRO2 were reduced and CVR was in-
creased significantly in aMCI patients when compared with
normal controls with similar age, sex, and education. Fur-
thermore, we observed that global brain perfusion was cor-
related with CMRO2 in the normal controls but not in
aMCI, suggesting the presence of neurovascular decoupling
in these patients. These findings collectively suggest that
compromised cerebral hemodynamics and/or CBF dysregu-
lation occur early at a prodromal stage of AD, which may
contribute to AD onset or progression.
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RESEARCH IN CONTEXT
1. Systematic review: Previous studies showed that re-
gional brain perfusion either was reduced or in-
creased in patients with aMCI. Whether or not
global brain perfusion and CMRO2 are altered in
aMCI is not clear. This study addressed this question
by measuring global brain perfusion and CMRO2 in
patients with aMCI using advanced ultrasonography
and NIR.
2. Interpretation: Global brain perfusion and CMRO2
were reduced and CVR was increased in aMCI
patients relative to the normal controls. In addition,
brain perfusion was correlated with CMRO2 in the
normal controls but not in aMCI. These findings col-
lectively suggest that cerebrovascular dysfunction
occurs at a prodromal stage of AD.
3. Future directions: Future applications of these
bedside-available methods into large population
studies will determine the clinical significance of the
findings presented here and unravel the role of cere-
brovascular dysfunction in AD onset and progression.
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